SMAD4 and pancreatic neoplasm: Similarly, our results showed that the most common gene alterations in the 118 pancreatic cancer patients studied were in KRAS (94.9%), TP53 (81.4%), CDKN2A (36.4%), and SMAD4 (22.9%).